RESILIENT-Ipsen (MM-398-01-03-04)

Study Information

Status: Active, Not Recruiting

Study Details

View study details on clinicaltrials.gov.

Locations

Not Specified

Clinical Trial FAQs

Information for patients and study volunteers, including frequently asked questions.

Description

A Randomized, Open Label Phase 3 Study of Irinotecan Liposome Injection (ONIVYDE®) versus Topotecan in Patients with Small Cell Lung Cancer Who Have Progressed on or after Platinum-based First-Line Therapy

The study will be conducted in two parts:

Dose determination of Irinotecan Liposome Injection

A randomized, efficacy study of Irinotecan Liposome Injection versus Topotecan

SIMR (Sacramento/Valley Area): Please contact simr@sutterhealth.org about study RESILIENT-Ipsen

Principal Investigator

Deepti Behl, MD

Co-Investigator(s)

Nitin Rohatgi, MD, Sivakumar Reddy, M.D., Jasdeepa Nagi, M.D., Vijay Suhag, M.D., Rajeswari Chellappah, M.D., Brian K. Kim, M.D, Kristin N. Arreola, M.D.

Funder

Ipsen Bioscience

Related Studies

SEER Lung Cancer

SEER-Lung: A Prospective Blood Sample Collection Study to Develop and Validate a Panel of Proteinbased Biomarkers in Patients with Pulmonary Nodules

Investigator: Tze-Ming Chen, M.D., FCCP

The Impact of Smoking, Comorbidities, and Race/Ethnicity on COVID-19 Infection and Disease Severity

Using EHR from a large healthcare system in Northern CA, we will study the impact of smoking, comorbidities, race on COVID-19 infection and disease severity.

Investigator: Jiang Li, Ph.D., MPH

We've expanded your view